John E Madias
Icahn School of Medicine at Mount Sinai/Cardiology Division, Elmhurst Hospital Center, New York, USA
*Corresponding author: John E Madias, Icahn School of Medicine at Mount Sinai/Cardiology Division, Elmhurst Hospital Center, New York, 11373, USA
Received: October 30, 2019
Published: November 16, 2019
LETTER TO THE EDITOR
Clinicians grappling with the enormous task of monitoring patients with acute decompensated heart failure (ADHF) in the hospital and the clinic would be very appreciative, had a reliable (i.e., sensitive and specific) biomarker was at hand, to be implemented. Unfortunately, such a biomarker has not emerged so far. Although N terminal pro-B type natriuretic peptide (NT proBNP) has been touted as such a biomarker its implementation has shown NT-proBNP to underperform as an instrument for guiding therapy in patients with ADHF, as it was recently shown in the PIMA II trial [1-3]. Indeed, NT proBNP-guided management did not significantly improve any of the primary or secondary event endpoints, in comparison with conventional management which was not aided by the use of NT proBNP .